anti-E antibody product blog
Tags: Antibody; Polyclonal Antibody; anti-E antibody; SARS Envelope;
The COVID-19 n/a (Catalog #MBS150849) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope antibody reacts with Virus and may cross-react with other species as described in the data sheet. MyBioSource\'s COVID 19 Envelope Coronavirus can be used in a range of immunoassay formats including, but not limited to, ELISA, Immunofluorescence (IF), Immunohistochemistry (IHC).IHC/IF: 1-3 ug/mL
Antibody validated: Immunohisochemistry and immunofuorescence in COVID-19 patient samples. SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope antibody can detect 50 ng of free peptide at 1 ?g/mL in ELISA. But it cannot detect envelope recombinant protein in WB and ELISA. Researchers should empirically determine the suitability of the COVID-19 n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The COVID-19 n/a product has the following accession number(s) (GI #1791269092) (Uniprot Accession #QHD43418). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Please refer to the product datasheet for known applications of a given antibody. We\'ve tested the SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope antibody with the following immunoassay(s):
Immunohistochemistry (IHC)/Immunofluorescence (IF) (Validation in COVID-19 Patient Sample. Detection of SARS-CoV-2 proteins in nasopharyngeal swab cell preparations F-H. Co-expression of spike detected by spike antibodies (MBS150780) and envelope proteins detected by envelope antibodies (MBS150849) of SARS-CoV-2 (panel F) documented localization of each protein to glandular cells with negative squamous cells two weeks after full revoery (panel G, signal yellow). No signal was seen in oral swabs of positive cases (Panel H). Both the spike and envelope protein detected by anti-spike antibodies (MBS150780) and anti-envelope antibodies (MBS150849) produced a signal in the nasopharyngeal swabs of the three vases and no signal was evident in the nasopharyngeal swabs of the seven controls.)
Immunohistochemistry (IHC) (IHC Validation in COVID-19 Patient Sample. Detection of SARS-CoV-2 Envelope protein in nasopharyngeal swab samples of COVID-19 patients Panel F shows Envelope protein detected by envelope antibodies (MBS150849) was still evident 2 weeks after the initial swabs (signal is red with hematoxylin counterstain), though the amount of virus was much less than at the initial swab.)
ELISA Test (Antibodies: SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope Antibody, (MBS150849) (1 ug/mL). A direct ELISA was performed using antigen or control peptide as coating antigen and the anti-SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope antibody as the capture antibody. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:20000 dilution. Detection range is from 32 ng/mL to 2000ng/mL.)
Immunohistochemistry (IHC) (IHC/IF Validation in COVID-19 Sample (Nuovo et al., 2020)
Detection of SARS-CoV-2 proteins in asopharyngeal swab cell preperations F-H. Co-expression of spike detected by spike antibodies (MBS150780) and envelope prot.)
Immunofluorescence (IF) (IF Validation of Envelope in COVID-19 Patient Skin (Magro et al., 2020) Detection of SARS-CoV-2 Envelope protein in the skin of COVID-19 patients that were confirmed by PCR. The skin staining shows Envelope protein expression (green)detected by envelope antibodies (MBS150849, 3 ug/mL) in mononuclear cells with hematoxylin counterstain. The staining was negative in control normal skin/lung (not shown).)
Immunofluorescence (IF) ( Immunofluorescence Validation of SARS-CoV-2 (COVID-19) Envelope in Human Lung Tissue from the COVID-19 Patient Immunofluoorescent l analysis of paraffin-embedded COVID-19 patient lung tissue using anti- SARS-CoV-2 (COVID-19) Envelope antibody (MBS150849, 2 ug/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4�C, followed by a goat anti-rabbit IgG secondary antibody at 1/500 (red) and DAPI staining (blue). (Courtesy of Dr. Nuovo Gerard J., OSU).)
Immunofluorescence (IF) (Co-expression of SARS-CoV-2 (COVID-19) Envelope and C5b-9 in Human Lung Tissue from the COVID-19 Patient Immunofluorescent l analysis of paraffin-embedded COVID-19 patient lung tissue using anti- SARS-CoV-2 (COVID-19) Envelope antibody (MBS150849, 2 ug/mL, red) and anti-C5b-9 antibody (green). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4�C, followed by secondary antibodies at 1/500 and DAPI staining (blue). Co- expression was shown in yellow. (Courtesy of Dr. Nuovo Gerard J., OSU).)
Immunohistochemistry (IHC) ( IHC Validation of Envelope in COVID-19 Patient Skin (Magro et al., 2020) Detection of SARS-CoV-2 Envelope protein in the blood vessels of COVID-19 patients that were confirmed by PCR. The staining shows Envelope protein expression (green) detected by envelope antibodies (MBS150849, 3 ug/mL) in the endothelial cytoplasms in thrombosed and normal appearing blood vessels with hematoxylin counterstain. The staining was negative in control normal skin/lung (not shown).)
Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019�20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Envelope protein is a small polypeptide that contains at least one ?-helical transmembrane domain. It involves in several aspects of the virus\'s life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication (3).